The PBC Journey

Target Audience

This educational activity will address identified knowledge and practice gaps related to the management of primary biliary cholangitis (PBC) among gastroenterologists, hepatologists, and specialist nurse practitioners (NPs) and physician associates (PAs).

Learning Objectives

Upon completion of this activity, participants should be better able to:

• Recognize symptoms, clinical signs, and laboratory markers associated with PBC to ensure timely evidence-based testing and diagnosis
• Monitor response to ursodeoxycholic acid and determine when to escalate treatment based on clinical goals and patient-specific factors
• Inform the selection of second-line and next therapies using the latest evidence and patient/disease profiles, including PBC-related symptoms and data on newer, peroxisome proliferator–activated receptor agonist therapies
• Develop individualized long-term management strategies that address age-related health concerns, comorbidities, and the clinical progression of disease

Program Overview

Primary biliary cholangitis (PBC) is a progressive autoimmune liver disease that can lead to liver failure and the need for liver transplantation if left untreated. PBC is commonly underdiagnosed or misdiagnosed, with an average delay of more than 3 years between presentation of symptoms/abnormal lab values and diagnosis. Recent advances in PBC management ­̶—including newer pharmacologic therapies and enhanced monitoring procedures—are reshaping practice and patient outcomes. This PBC Patient Journey™ activity will immerse learners in a longitudinal, real-

world case that reflects the lived experience of a patient with PBC. Through integrated patient narratives and expert clinician commentary, participants will explore diagnostics, treatment options, monitoring schedules, and comprehensive care strategies that will aim to improve practice and patient care. 

Physician Accreditation Statement

Integritas Communications is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physician Credit Designation

Integritas designates this enduring activity for a maximum of 1.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nursing Continuing Education

Global Education Group is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation.

This educational activity for 1.25 contact hour, including 0.0 pharmacotherapeutic contact hours, is provided by Global Education Group. Nurses should claim only the credit commensurate with the extent of their participation in the activity.

Instructions to Receive Credit

In order to receive credit for this activity, the participant must complete the pretest, pass the posttest with a 70% score or higher, and submit an evaluation form.

Fee Information

There is no fee for this activity.

Disclosures of Conflicts of Interest

Integritas Communications and Global adhere to the policies and guidelines, including the Standards for Integrity and Independence in Accredited CE, set forth to providers by the Accreditation Council for Continuing Medical Education (ACCME) and all other professional organizations, as applicable, stating those activities where continuing education credits are awarded must be balanced, independent, objective, and scientifically rigorous. All persons in a position to control the content of an accredited continuing education program provided by Global are required to disclose all financial relationships with any ineligible company within the past 24 months to Global.  All financial relationships reported are identified as relevant and mitigated by Global in accordance with the Standards for Integrity and Independence in Accredited CE in advance of delivery of the activity to learners. The content of this activity was vetted by Global to assure objectivity and that the activity is free of commercial bias.   

All relevant financial relationships have been mitigated. 

The faculty have the following relevant financial relationships with ineligible companies:

HoChong Gilles, DNP, FNP-BC, AF-AASLD:

Consulting Fees: Boehringer Ingelheim, Gilead Sciences Inc., Ipsen, Madrigal, Mallinckrodt, Novo Nordisk

Aparna Goel, MD:

Consulting Fees: Gilead Life Sciences, Ipsen Pharmaceuticals, Mirum

Contracted Research: Gilead Life Sciences

Alyson (patient):

Nothing to disclose.

The planners and managers at Integritas Communications and Global Education Group have no relevant financial relationships to disclose.

Disclosure of Unlabeled Use

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Contact Information